Clinical trial
Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
NCT00461149 · Federico II University, Other · Completed
Key facts
| NCT number | NCT00461149 |
|---|---|
| Title | Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly |
| Official title | Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly |
| Acronym | HDacro |
| Lead sponsor | Federico II University, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Octreotide-LAR |
| Enrollment | 50 |
| Start date | Jan 1, 1995 |
| Completion | Dec 1, 2006 |
| First posted | Apr 17, 2007 |
| Last update posted | Apr 17, 2007 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: